Is cervical cancer vaccine just approved out of date in China? The manufacturer announced that the product was withdrawn from the US market

Source: surging news: on October 26, 2016, GlaxoSmithKline (GSK), the British pharmaceutical giant that just announced that it had obtained approval for cervical cancer vaccine in China, suddenly announced three months later that it had withdrawn from the earliest market - the United States According to foreign medical website fierce Pharma on October 21, a spokesman for GlaxoSmithKline disclosed to it: "due to the very low demand for human papillomavirus (HPV) vaccine (commonly known as cervical cancer vaccine)" Cervarix "in the U.S market, GlaxoSmithKline has decided to delist it from the U.S market." On October 25, the head of GlaxoSmithKline China confirmed the news to surging news (www.thepaper CN) The person in charge said that the delisting was due to the lack of demand in the US market Foreign media reported that a spokesman for GlaxoSmithKline pointed out that "due to the similar products on the market in the United States, the market demand for Hirsch is very low, so we consider to stop supply to the U.S market based on this, but Hirsch's access to the FDA's listing license is still effective, and Hirsch has been approved by 107 regulators, covering the world 136 countries " According to the data, in 2015, the sales volume of "Hirsch" in the world was $135 million, including about $5 million in the U.S market, with a share of less than 4%; in the first half of this year, the global sales volume of "Hirsch" was $48 million, with a total sales volume of $1 million in the U.S market, with a share of about 2% Original details: http://news.bioon.com/article/6691709.html